SMU-L11
Product Specifications
UNSPSC Description
SMU-L11 is a specific TLR7 agonist (EC50=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4+ T and CD8+ T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases[1].
Target Antigen
MAPKAPK2 (MK2); NF-κB; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation;MAPK/ERK Pathway;NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/smu-l11.html
Solubility
10 mM in DMSO
Smiles
CCCCC1=NC2=C(N1CC3CCOC3)C4=CC=CC=C4N=C2N
Molecular Weight
324.42
References & Citations
[1]Ou J, et al. Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma. J Med Chem. 2024 Feb 16.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-157793/SMU-L11-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-157793/SMU-L11-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
